fbpx
A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

Chairside Oral HPV Test in Development

0

Today’s patients often expect instant results, and now researchers are one step closer to developing a rapid oral human papillomavirus (HPV) test that could deliver chairside results. The test would enable medical and oral health professionals to test for HPV —which is linked to cervical and oropharyngeal cancer — via an oral assay. At the center of this development is Jennifer Webster-Cyriaque, PhD, a professor at the University of North Carolina at Chapel Hill Schools of Dentistry and Medicine, who is co-investigating the rapid oral test in collaboration with Sunnyvale, California-based InSilixa Inc. “There is no oral HPV test currently available, and persistence of high-risk HPV types is an important risk factor for cancer development,” she says. “This test would detect HPV in saliva, and it would be selective for types of the virus that are highest risk for causing oral cancer.” InSilixa plans to formulate the test developed in Webster-Cyriaque’s lab as a chairside diagnostic suitable for widespread clinical use. The company has received a Phase 1 Small Business Innovation Research grant from the National Institutes of Health to support the test’s development. Today’s patients often expect instant results, and now researchers are one step closer to developing a rapid oral human papillomavirus (HPV) test that could deliver chairside results. The test would enable medical and oral health professionals to test for HPV — which is linked to cervical and oropharyngeal cancer — via an oral assay. At the center of this development is Jennifer Webster-Cyriaque, PhD, a professor at the University of North Carolina at Chapel Hill Schools of Dentistry and Medicine, who is co-investigating the rapid oral test in collaboration with Sunnyvale, California-based InSilixa Inc. “There is no oral HPV test currently available, and persistence of high-risk HPV types is an important risk factor for cancer development,” she says. “This test would detect HPV in saliva, and it would be selective for types of the virus that are highest risk for causing oral cancer.”

InSilixa plans to formulate the test developed in Webster-Cyriaque’s lab as a chairside diagnostic suitable for widespread clinical use. The company has received a Phase 1 Small Business Innovation Research grant from the National Institutes of Health to support the test’s development.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

SAVE BIG ON CE BEFORE 2025!

:
:
:
Coupon has expired

Promotional Period: 12/14/24 – 12/31/24

Get Special CE Savings!